The Pediatric Infectious Disease Journal  •  Volume 35, Number 5, May 2016

with children without any clinical complaints. Additionally, high fecal Ct values (reflecting low viral load) were found in HPeV3-infected children with severe disease without a coinfection and low Ct values (indicating a high viral load) in asymptomatic children. This confirms the results of earlier studies, in which high viral loads were found in asymptomatic children.9 In addition, the initial Ct value during symptomatic disease did not differ between children with mild and severe disease, but Ct value in HPeV3-infected children was significantly higher when compared with HPeV1-infected children. In a previous study, we found that the Ct value in children with severe HPeV3 disease (mainly meningitis/encephalitis) was significantly higher than in HPeV3-infected children with other diagnoses.3 The lower viral load in feces can be a result of differences in cell tropism of HPeV3 as is suggested by Westerhuis et al10; HPeV3 strains that caused central nervous system symptoms in the patients they were derived from, showed better replication kinetics in neural cell lines. In addition, replication kinetics on one gastrointestinal cell line (Caco-2) were high for all HPeV3 strains but low or absent on another gastrointestinal cell line (HT29), whereas replication for HPeV1 was high for both cell lines. These results have to be interpreted with caution because they are derived from in vitro experiments with continuous growing cell lines, which do not necessarily represent gastrointestinal cells in vivo. However, our results implicate that even high Ct values in feces of HPeV3infected children can be of clinical relevance and, second, that the viral load in feces is not a good instrument for evaluating severity of infection. In conclusion, after symptomatic infection shedding of HPeV1, HPeV3 and HPeV4 in feces can occur for months in infants. Viral load (Ct-value) cannot differentiate between asymptomatic shedding and symptomatic infection nor between severe and mild disease. REFERENCES 1. Harvala H, Simmonds P. Human parechoviruses: biology, epidemiology and clinical significance. J Clin Virol. 2009;45:1–9. 2. Benschop K, Molenkamp R, van der Ham A, et al. Rapid detection of human parechoviruses in clinical samples by real-time PCR. J Clin Virol. 2008;41:69–74. 3. Wildenbeest JG, Benschop KS, Minnaar RP, et al. Clinical relevance of positive human parechovirus type 1 and 3 PCR in stool samples. Clin Microbiol Infect. 2014;20:O640–O647. 4. Tapia G, Cinek O, Witsø E, et al. Longitudinal observation of parechovirus in stool samples from Norwegian infants. J Med Virol. 2008;80:1835–1842. 5. Tapia G, Cinek O, Rasmussen T, et al. Human enterovirus RNA in monthly fecal samples and islet autoimmunity in Norwegian children with high genetic risk for type 1 diabetes: the MIDIA study. Diabetes Care. 2011;34:151–155. 6. Kolehmainen P, Oikarinen S, Koskiniemi M, et al. Human parechoviruses are frequently detected in stool of healthy Finnish children. J Clin Virol. 2012;54:156–161. 7. Benschop K, Thomas X, Serpenti C, et al. High prevalence of human Parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol. 2008;46:3965–3970. 8. Verboon-Maciolek MA, Groenendaal F, Hahn CD, et al. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol. 2008;64:266–273. 9. Zhang DL, Jin Y, Li DD, et al. Prevalence of human parechovirus in Chinese children hospitalized for acute gastroenteritis. Clin Microbiol Infect. 2011;17:1563–1569. 10. Westerhuis BM, Koen G, Wildenbeest JG, et al. Specific cell tropism and neutralization of human parechovirus types 1 and 3: implications for pathogenesis and therapy development. J Gen Virol. 2012;93(Pt 11):2363– 2370.

© 2016 Wolters Kluwer Health, Inc. All rights reserved.

Influenza Virus Shedding

THE TIMELINE OF INFLUENZA VIRUS SHEDDING IN CHILDREN AND ADULTS IN A HOUSEHOLD TRANSMISSION STUDY OF INFLUENZA IN MANAGUA, NICARAGUA Sophia Ng, PhD,* Roger Lopez, BSc,† Guillermina Kuan, MD,‡ Lionel Gresh, PhD,§ Angel Balmaseda, MD,† Eva Harris, PhD,¶ and Aubree Gordon, PhD, MPH* Abstract: In a household transmission study in Nicaragua, children under 6 years old had a longer duration of presymptomatic influenza virus shedding than adults. The duration of postsymptomatic influenza virus shedding was longest in children 0–5 years old, followed by children 6–15 years of age and adults. Key Words: influenza virus shedding, presymptomatic, postsymptomatic, children, adults Accepted for publication December 21, 2015. From the *Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan; †Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua; ‡Centro de Salud Sócrates Flores Vivas Health Center, Ministry of Health, Managua, Nicaragua; §Sustainable Sciences Institute, Managua, Nicaragua; and ¶Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California. This study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Grant Number U01AI088654 (to A.G. and E.H.) and Contract Number HHSN272201400006C, and was funded through a career development award from the John E. Fogarty International Center, National Institutes of Health (K02 TW009483 to A.G.). The authors have no conflicts of interest to disclose. Address for correspondence: Aubree Gordon, PhD, MPH, School of Public Health, University of Michigan, Ann Arbor, MI 48109. E-mail: [email protected]. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com). Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. DOI: 10.1097/INF.0000000000001083

B

asic knowledge of the timeline of virus shedding is crucial for a full understanding of influenza transmission and control. Children are particularly prone to influenza infection and are an important source of influenza transmission. Duration of influenza virus shedding is commonly measured as time to shedding cessation following symptom onset even though presymptomatic virus shedding occurs in children.1–5 Some studies have found that the duration of viral shedding in children may be longer than in adults, however, this has not been consistently reported across studies2,3,6,7 In this study, we aim to characterize pre- and postsymptomatic viral shedding duration using data from a case-based ascertainment household study in Nicaragua. The agespecific event times of viral shedding onset and cessation are described and compared. We also explore how sex, antiviral use and influenza types and subtypes may explain heterogeneity in viral shedding.

METHODS Participants and Procedures The Nicaraguan Pediatric Influenza Cohort Study is an ongoing study based in the Health Center Sócrates Flores Vivas in Managua, Nicaragua, which is the government health center that serves the catchment area of District II. Patients who attended the Health Center Sócrates Flores Vivas for medical care were screened for their eligibility to participate in an influenza household transmission study. Index cases were recruited both from the pediatric cohort study8 and the national influenza surveillance program. Patients who (1) had a positive QuickVue Influenza A+B rapid test result, (2) experienced symptom onset of an acute respiratory www.pidj.com | 583

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

Ng et al

The Pediatric Infectious Disease Journal  •  Volume 35, Number 5, May 2016

infection (ARI) within the previous 48 hours and (3) lived with at least one other household member were invited to participate. A nasal and oropharyneal swab and daily symptom history were collected from consented patients at the Health Center. Household members were monitored for influenza infection through 5 home visits conducted every 2–3 days over a period of 10–14 days beginning with the identification of the index influenza case. During each visit, the index cases and their household members provided additional nasal and oropharyneal swabs. Additional respiratory samples were collected if the participant presented at the health center in the 30 days following enrollment. Signs and symptoms of ARI included fever or feverish, cough, sore throat, runny nose, malaise, muscle or joint pain, difficulty breathing, respiratory sounds, nasal flaring and chest indrawing. Participants provided written informed consent and parental permission was obtained from parents or legal guardians of children. In addition, verbal assent was obtained from children aged 6 years and older. The study was conducted in accordance with the Helsinki Declaration and was approved by Institutional Review Boards at the following institutions: (1) University of Michigan, (2)

Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Nicaragua and (3) University of California, Berkeley.

Laboratory Methods Combined nasal and orophyreangeal swabs were collected from all participants and placed in a single tube of viral transport media. Specimens were maintained at 4°C and sent within 48 hours to the National Virology Laboratory at the Nicaraguan Ministry of Health on the day of collection. The samples were tested in the National Virology Laboratory by real-time reverse-transcription polymerase chain reaction (rRT-PCR) using standard protocols validated by the Centers for Disease Control and Prevention.9

Statistical Analyses The primary outcome measure for viral shedding was rRTPCR positivity. Survival analyses estimated (1) time from symptom onset to viral shedding onset, 2) time from symptom onset to viral shedding cessation and (3) viral shedding duration, that is, the duration between viral shedding onset and cessation. The analyses allowed event times of viral shedding onset and cessation to be censored,

FIGURE 1.  Persistence of viral shedding within 20 days of viral shedding onset stratified by sex.

584  |  www.pidj.com

© 2016 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

The Pediatric Infectious Disease Journal  •  Volume 35, Number 5, May 2016

and took into account within-household clustering.10 Viral shedding onset of index cases was left censored whereas left, right or interval censoring may occur for shedding in household contacts. All statistical analyses were conducted in R version 3.1.3. Technical details of the statistical methods are presented in the Supplementary Materials (Supplemental Digital Content 1, http://links.lww.com/INF/C402).

RESULTS A total of 168 index cases and 668 household contacts were recruited during 2012–2014, when influenza A(H1N1)pdm09, A/ H3N2/Perth/16/2009-like, A/Texas/50/2012-like and B (Yamagata and Victoria-lineages) circulated. Among those recruited, 144 index cases and 112 household contacts had rRT-PCR confirmation of influenza infection. Eight vaccinated rRT-PCR-positive participants were excluded because this study is underpowered to estimate the effect of vaccination. These analyses focus on describing the timeline of viral shedding in relation to symptom onset date. Twenty-eight rRT-PCR positive household contacts who did not show any signs or symptoms of ARI were excluded from the main analyses. The percentage of rRT-PCR confirmed household contacts 0–5 years old who showed signs or symptoms of ARI was 32.1%, compared with 21.4% and 20.5% among contacts 6–15 years old and adult contacts, respectively. The mean body temperature on

Influenza Virus Shedding

the date of symptom onset (if any) for rRT-PCR confirmed cases among household contacts were 38.0°C for children 0–5 years old, 37.9°C for 6–15 years old and 38.0°C for adults. The main analyses included 220 rRT-PCR positive individuals who showed ARI symptoms; among them, 61% received Oseltamivir. rRT-PCR positivity was observed as early as 5 days before symptom onset, and at the latest 21 days after symptom onset. Therefore, event times were corrected by +5 days to allow for presymptomatic shedding in our analyses.

Time from Illness Onset to Onset of Viral Shedding Univariate analyses estimated that 69% of children 0 to 5 years old, 67% of children 6 to 15 years old and 45% of adults (16 years old or above) showed presymptomatic viral shedding. The median time from symptom onset to viral shedding onset was −1.1 days (interquartile range, IQR: 2.3, 0.4) for young children, −1 day (IQR: −2.2, 0.5) for older children and 0.2 days (IQR: −1.2, 2.3) for adults. Since no differences were found in the event times of viral shedding onset and cessation between males and females (Fig. 1), we included only age group and influenza type and subtype as covariates in our main analysis. There were no detectable differences in time from symptom onset to viral shedding onset between

FIGURE 2.  Persistence of viral shedding within 20 days of viral shedding onset. © 2016 Wolters Kluwer Health, Inc. All rights reserved.

www.pidj.com | 585

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

The Pediatric Infectious Disease Journal  •  Volume 35, Number 5, May 2016

Ng et al

young and older children [acceleration factor (AF): 1.13; 95% credibility intervals [CI]: 0.90, 2.10; see Table, Supplemental Digital Content 2, http://links.lww.com/INF/C403]. Adults started shedding virus 53% later than young children (AF: 1.53, 95% CI: 1.19, 2.10), that is, approximately 2 days later. No significant differences were detected by influenza virus types/subtypes.

Time from Illness Onset to Viral Shedding Cessation Univariate analyses estimated the median time from symptom onset to viral shedding cessation was 3.1 days (IQR: 2.2, 4.4) for young children, 2.3 days (IQR: 1.6, 3.7) for older children and 2.7 days (IQR: 1.9, 4.0) for adults. Only 19% of subjects who had taken Oseltamivir completed a full course of medication (5 days). No significant association was found between Oseltamivir use, sex and viral shedding cessation (Figure 1 & Table, Supplemental Digital Content 3, http://links.lww.com/INF/C404). The estimated time from symptom onset to viral shedding cessation was 47% shorter for adults compared with young children (AF: 0.53; 95% CI: 0.42, 0.67), that is, approximately 4 days shorter (Table, Supplemental Digital Content 2, http://links.lww.com/INF/C403). The estimated time was 20% shorter for older children compared with young children (AF: 0.80; 95% CI: 0.66, 0.96), that is, approximately half a day shorter. Individuals who had influenza coinfection stopped shedding virus 56% later compared with A(H1N1)pdm09 infection alone (AF: 1.56; 95% CI: 1.04, 2.36).

Total Viral Shedding Duration Figure 2 shows the survival curves for influenza virus-specific shedding. Each panel represents the proportion of participants that were still rRT-PCR positive within 20 days of viral shedding onset. Viral shedding duration was shortest in adults, and older children had a tendency to shed the virus for a shorter duration compared with younger children. Sensitivity analyses including index cases and household contacts in separate models generated consistent results.

DISCUSSION In our study, we found that children started to shed influenza virus earlier than adults and that presymptomatic viral shedding was frequently observed. Children also continued to shed virus longer than adults after illness onset. Previous systematic reviews did not find consistent results comparing viral shedding duration between children and adults.6,7 Our findings are consistent with 2 other cohort studies that included presymptomatic viral shedding in their analyses.2,3 Our analyses highlight a new finding that onset of rRT-PCR positivity occurred earlier in children compared with adults. Pre-existing immunity may determine early control of virus replication, and children often have lower pre-existing influenzaspecific antibodies compared with adults. Further studies should examine the relationship of immune correlates of protection with influenza virus shedding to identify the biological mechanism that explains the observed age-related differences. There are several limitations to our study. First, respiratory specimens were collected every 2 to 3 days. More frequent specimen collection may improve the accuracy of our estimates. The use of rRT-PCR positivity is not a perfect measure for infectiousness since nonviable influenza viruses can be detected. On the contrary, rRT-PCR might not be able to detect low-level virus shedding, leading to underestimation in shedding duration. The use of quantitative RT-PCR would have allowed us to characterize change in infectiousness during the course of infection. rRT-PCR status can be affected by the quality of respiratory specimens. We detected a high (16%) secondary attack rate of rRT-PCR-confirmed infections among household contacts, which indicates our study was

586  |  www.pidj.com

efficient in detecting viral shedding. It is possible that there were systematically longer delays in reporting illness onset for young children Potential differences in shedding risk might exist between those who took Oseltamivir and those who did not, leading to spurious null association between Oseltamivir use and viral shedding. Finally, our study may be underpowered to detect small differences between genders and influenza subtypes/types.

ACKNOWLEDGMENTS We thank the families that participated in the study and our study staff at the Health Center Sócrates Flores Vives and at the Centro Nacional de Diagnostico y Referencia. REFERENCES 1. Suess T, Remschmidt C, Schink SB, et al. Comparison of shedding characteristics of seasonal influenza virus (sub)types and influenza A(H1N1) pdm09; Germany, 2007–2011. PLoS One. 2012;7:e51653. 2. Loeb M, Singh PK, Fox J, et al. Longitudinal study of influenza molecular viral shedding in Hutterite communities. J Infect Dis. 2012;206:1078–1084. 3. Lau LLH, Ip DKM, Nishiura H, et al. Heterogeneity in virus shedding among medically-attended influenza A virus infections. J Infect Dis. 2013;207:1281–1285. 4. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433–441. 5. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med. 2010;362:2175–2184. 6. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:775–785. 7. Fielding JE, Kelly HA, Mercer GN, et al. Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses. 2014;8:142–150. 8. Gordon A, Saborío S, Videa E, et al. Clinical attack rate and presentation of pandemic H1N1 influenza versus seasonal influenza A and B in a pediatric cohort in Nicaragua. Clin Infect Dis. 2010;50:1462–1467. 9. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N Engl J Med. 2009;360:2605–2615. 10. KomÁrek A, Lesaffre E. Bayesian accelerated failure time model with multivariate doubly interval-censored data and flexible distributional assumptions. J Am Stat Assoc. 2008;103:523–533.

IMPACT OF THE INCREASED RECOMMENDED DOSAGE OF ISONIAZID ON PYRIDOXINE LEVELS IN CHILDREN AND ADOLESCENTS Diana Rodà, MD,* Librada Rozas, MSc, RN,† Clàudia Fortuny, MD, PhD,* Cristina Sierra, MD, PhD,‡ and Antoni Noguera-Julian, MD, PhD* Abstract: Isoniazid exposure causes dose-dependent pyridoxine deficiency. Recently, the recommended dosage of isoniazid in children was increased from 5 (4–6) to 10 (10–15) mg/kg/day. We aimed to analyze longitudinally pyridoxine levels in a cohort of previously healthy children and adolescents treated with isoniazid. Mild symptom-free pyridoxine deficiency was observed in 4/75 (5.6%) and 3/40 (7.5%) at baseline and at 3-month followup, respectively. Classical age-related risk factors identified patients at risk of pyridoxine deficiency. Our preliminary results support current recommendations regarding pyridoxine supplementation in healthy children. Key Words: isoniazid, peripheral neuropathy, pyridoxine, tuberculosis, vitamin B6 Accepted for publication November 2, 2015. From the *Infectious Diseases Unit, Pediatrics Department, and †Pediatric Tuberculosis Unit, Nursing Department, Hospital Sant Joan de Déu-Universitat de

© 2016 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2016 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

The Timeline of Influenza Virus Shedding in Children and Adults in a Household Transmission Study of Influenza in Managua, Nicaragua.

In a household transmission study in Nicaragua, children under 6 years old had a longer duration of presymptomatic influenza virus shedding than adult...
565B Sizes 0 Downloads 11 Views